US · IMTX · BIOTECHNOLOGY
Immatics N.V. (IMTX) intrinsic value and stock valuation
$5.77as of 2026-11-21 · Mkt cap 1.29B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Immatics N.V. DCF and intrinsic value
InvestorsCraft values IMTX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IMTX’s statements →
Immatics N.V. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $48.3M | $155.8M | $54M | $172.8M | $34.8M |
| Operating income | -$-182.02M | -$-38.62M | -$-101.72M | $30M | -$-86.29M |
| Net income | -$-196.45M | $15.2M | -$-96.99M | $37.5M | -$-95.06M |
| EPSd | -$-1.61M | $142.5K | -$-1.2M | $545K | -$-1.51M |
| Operating cash flow | -$-169.66M | -$-158.03M | $18.2M | $100.1M | -$-81.78M |
| Capital expenditure | -$-6.3M | -$-16.48M | -$-30.96M | -$-6.21M | -$-5.66M |
| Free cash flow | -$-175.95M | -$-174.51M | -$-12.73M | $93.9M | -$-87.44M |
| Total assets | $562.1M | $696.2M | $510M | $407.8M | $174.7M |
| Total debt | $15.6M | $16.2M | $15.4M | $14.6M | $9.85M |
| Net debt | -$-330.14M | -$-220.54M | -$-203.07M | -$-133.96M | -$-123.14M |
| Total equity | $483.9M | $574.8M | $225.1M | $213.2M | $24.1M |
| Cash and short-term investments | $469.1M | $604.5M | $425.9M | $362.2M | $145.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $48.3M | $155.8M | $54M | $172.8M | $34.8M |
| Cost of revenue | $0.00 | $0.00 | $118.7M | $106.8M | $87.6M |
| Gross profit | $48.3M | $155.8M | -$-64.67M | $66.1M | -$-52.81M |
| Research and development expenses | $183.8M | $148.1M | $118.7M | $106.8M | $87.6M |
| Selling, general and administrative expenses | $51.2M | $46.5M | $38.2M | $36.1M | $33.8M |
| Other expenses | -$-4.73M | -$-80K | -$-1.14M | -$-30K | -$-330K |
| Operating expenses | $230.3M | $194.5M | $155.7M | $142.9M | $121.1M |
| Cost and expenses | $230.3M | $194.5M | $155.7M | $142.9M | $121.1M |
| Interest income | $17.2M | $25M | $13.9M | $2.48M | $130K |
| Interest expense | $950K | $890K | $830K | $1.04M | $570K |
| Depreciation and amortization | $12.4M | $12.2M | $7.23M | $6.84M | $5.47M |
| Ebitda | -$-185.09M | $34.5M | -$-88.93M | $50M | -$-87.3M |
| Operating income | -$-182.02M | -$-38.62M | -$-101.72M | $30M | -$-86.29M |
| Total other income/expenses, net | -$-16.42M | $60M | $4.73M | $12.1M | -$-7.04M |
| Income before tax | -$-198.44M | $21.4M | -$-96.99M | $42M | -$-93.33M |
| Income tax expense | -$-1.99M | $6.13M | $0.00 | $4.55M | $0.00 |
| Net income | -$-196.45M | $15.2M | -$-96.99M | $37.5M | -$-95.06M |
| Weighted average shares outstanding | $122.4M | $108.7M | $80.6M | $67.2M | $62.9M |
| Weighted average diluted shares outstanding | $122.4M | $106.8M | $80.6M | $68.8M | $62.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $469.1M | $604.5M | $425.9M | $362.2M | $145.1M |
| Net receivables | $6.88M | $6.75M | $5.74M | $1.11M | $2.36M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $503.8M | $629.6M | $449.4M | $377.2M | $152.2M |
| Property, plant and equipment, net | $54.9M | $63.7M | $57.1M | $26.5M | $20.5M |
| Goodwill and intangible assets | $1.58M | $1.63M | $1.52M | $1.63M | $1.31M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $58.3M | $66.6M | $60.6M | $30.7M | $22.4M |
| Total assets | $562.1M | $696.2M | $510M | $407.8M | $174.7M |
| Accounts payable | $340K | $10.1M | $7.67M | $4.03M | $3.01M |
| Short-term debt | $2.76M | $2.85M | $2.6M | $2.16M | $2.71M |
| Deferred revenue | $15.8M | $35.9M | $100.4M | $65M | $50.4M |
| Total current liabilities | $43M | $68M | $156.6M | $106.5M | $95.2M |
| Long-term debt | $12.9M | $13.4M | $12.8M | $12.4M | $7.14M |
| Deferred revenue, non-current | $18.5M | $34.2M | $115.5M | $75.8M | $48.2M |
| Total non-current liabilities | $35.2M | $53.3M | $128.3M | $88.2M | $55.4M |
| Capital lease obligations | $15.6M | $16.2M | $15.4M | $14.6M | $9.85M |
| Total liabilities | $78.2M | $121.3M | $284.9M | $194.7M | $150.6M |
| Common stock | $1.34M | $1.22M | $850K | $770K | $630K |
| Retained earnings | -$-785.65M | -$-589.54M | -$-597.29M | -$-500.3M | -$-537.81M |
| Accumulated other comprehensive income (loss) | -$-8.59M | $1.03M | -$-1.64M | -$-1.48M | -$-3.94M |
| Total equity | $483.9M | $574.8M | $225.1M | $213.2M | $24.1M |
| Total investments | $123.4M | $367.7M | $207.4M | $213.7M | $12.1M |
| Total debt | $15.6M | $16.2M | $15.4M | $14.6M | $9.85M |
| Net debt | -$-330.14M | -$-220.54M | -$-203.07M | -$-133.96M | -$-123.14M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-188.69M | $15.2M | -$-94.65M | $37.5M | -$-93.33M |
| Depreciation and amortization | $11.9M | $12.2M | $7.23M | $6.97M | $5.26M |
| Stock-based compensation | $0.00 | $17.6M | $20.7M | $22.6M | $26.4M |
| Change in working capital | -$-42.23M | -$-163.88M | $81.6M | $37.3M | -$-31.7M |
| Accounts receivable | -$-230K | -$-1.76M | -$-2.98M | -$-430K | $570K |
| Inventory | $0.00 | $0.00 | -$-84.24M | $0.00 | $0.00 |
| Accounts payable | -$-36.13M | $0.00 | $84.2M | $45.6M | -$-31.78M |
| Net cash provided by operating activities | -$-169.66M | -$-158.03M | $18.2M | $100.1M | -$-81.78M |
| Investments in property, plant and equipment | -$-6.54M | -$-16.27M | -$-30.8M | -$-6.21M | -$-5.66M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-199.91M | $550K |
| Net cash used for investing activities | $196.7M | -$-152.39M | -$-31.39M | -$-209.79M | $7.49M |
| Common stock issued | $96.4M | $343M | $90.4M | $134.5M | $90K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $93.5M | $319.7M | $84.5M | $123.7M | -$-2.61M |
| Net change in cash | $137.1M | $18.3M | $70M | $15.5M | -$-74.54M |
| Cash at end of period | $345.8M | $236.8M | $218.5M | $148.5M | $133M |
| Operating cash flow | -$-169.66M | -$-158.03M | $18.2M | $100.1M | -$-81.78M |
| Capital expenditure | -$-6.3M | -$-16.48M | -$-30.96M | -$-6.21M | -$-5.66M |
| Free cash flow | -$-175.95M | -$-174.51M | -$-12.73M | $93.9M | -$-87.44M |
Line items
Line items
Line items
About Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
- CEO
- Harpreet Singh
- Employees
- 678
- Beta
- 1.32
Explore
Frequently asked questions
What is the intrinsic value of Immatics N.V. (IMTX)?
Immatics N.V. (IMTX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is IMTX undervalued?
IMTX trades at a price of $5.77 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.